Compare · BTMD vs DFTX
BTMD vs DFTX
Side-by-side comparison of Biote Corp. (BTMD) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTMD and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.31B, about 110.6x BTMD ($39.0M).
- Over the past year, BTMD is down 64.0% and DFTX is up 150.6% - DFTX leads by 214.6 points.
- DFTX has hit the wire 8 times in the past 4 weeks while BTMD has been quiet.
- DFTX has more recent analyst coverage (8 ratings vs 4 for BTMD).
PerformanceBTMD-63.99%DFTX+150.61%
2025-10-20+0.00%2026-10-19
- Company
- Biote Corp.
- Definium Therapeutics Inc.
- Price
- $1.05-4.52%
- $32.95+2.60%
- Market cap
- $39.0M
- $4.31B
- 1M return
- -21.85%
- -15.09%
- 1Y return
- -63.99%
- +150.61%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 8
- Recent ratings
- 4
- 8
Latest BTMD
- Executive Chairman Beer Marc D bought $202,204 worth of shares (131,950 units at $1.53), increasing direct ownership by 122% to 239,744 units (SEC Form 4)
- SEC Form 10-Q filed by Biote Corp.
- Biote Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biote Reports Second Quarter 2026 Financial Results
- Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call
- Amendment: SEC Form 8-K/A filed by Biote Corp.
- SEC Form 4 filed by Interim CEO Peterson Robert Charles
- SEC Form 4 filed by Director Christensen Bret
- SEC Form 4 filed by Executive Chairman Beer Marc D
- Biote Corp. filed SEC Form 8-K: Leadership Update
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.